Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.54 |
| ▸ | WNT3A | P56704 | 10/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474396 | 0.82 | LMNA (0.56) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL31475594 | 0.82 | LMNA (0.56) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL8489375 | 0.82 | LMNA (0.56) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL1128084 | 0.81 | LMNA (0.70) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL8232789 | 0.81 | CTNNB1 (0.57) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL30089582 | 0.81 | CTNNB1 (0.75) | LMNAGAACTNNB1WNT3ACNR2 | |
| Ammonia Solution, Strong SCHEMBL28847475 | 0.80 | CTNNB1 (0.55) | LMNAGAACTNNB1WNT3APTGS1 | |
| Hydrochloric Acid SCHEMBL4500907 | 0.80 | CTNNB1 (0.55) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL19858887 | 0.79 | CTNNB1 (0.58) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL2073272 | 0.79 | CTNNB1 (0.58) | LMNAGAACTNNB1WNT3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102256972-A | Thiazolyl-benzimidazoles | HOFFMANN LA ROCHE | 2011-11-23 | — | — | CN | disclosed |
| EP-2379543-A2 | THIAZOLYL-BENZIMIDAZOLES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010121675-A2 | THIAZOLYL-BENZIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | LMNA 3399/4885GAA 168/4885CTNNB1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.